1. History of laboratory confirmed MERS, SARS-CoV-1 or SARS-CoV-2 infection 2. Seropositive for SARS-CoV-2 Nucleocapsid IgG at screening 3. Have an anti-SARS-CoV-2 and a SARS-CoV-1 RBD response of more than 2 AUC (Area Under the Curve) units 4. Planned receipt of any vaccine other than the study intervention within 30 days before and after each study vaccination. 5. Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate. 6. Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection, asplenia, recurrent severe infections and use of immunosuppressant medication within the past 6 months, except topical steroids or short-term oral steroids (course lasting <14 days). 7. Any autoimmune conditions, except mild psoriasis, well-controlled autoimmune thyroid disease, vitiligo or stable coeliac disease not requiring immunosuppressive or immunomodulatory therapy. 8. History of allergic disease or reactions likely to be exacerbated by any component of the pEVAC-PS vaccine 9. Any history of angioedema. 10. Any history of anaphylaxis. 11. Pregnancy, lactation or willingness/intention to become pregnant for 3 months following the last personal dose of vaccine in this trial.

1. History of laboratory confirmed MERS, SARS-CoV-1 or SARS-CoV-2 infection 2. Seropositive for SARS-CoV-2 Nucleocapsid IgG at screening 3. Have an anti-SARS-CoV-2 and a SARS-CoV-1 RBD response of more than 2 AUC (Area Under the Curve) units 4. Planned receipt of any vaccine other than the study intervention within 30 days before and after each study vaccination. 5. Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate. 6. Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection, asplenia, recurrent severe infections and use of immunosuppressant medication within the past 6 months, except topical steroids or short-term oral steroids (course lasting <14 days). 7. Any autoimmune conditions, except mild psoriasis, well-controlled autoimmune thyroid disease, vitiligo or stable coeliac disease not requiring immunosuppressive or immunomodulatory therapy. 8. History of allergic disease or reactions likely to be exacerbated by any component of the pEVAC-PS vaccine 9. Any history of angioedema. 10. Any history of anaphylaxis. 11. Pregnancy, lactation or willingness/intention to become pregnant for 3 months following the last personal dose of vaccine in this trial.